東華大學圖書館 |

Effects of Anti-Oxidative and Cholesterol Lowering Capacities of Selected Edible-Medicinal Mushrooms Towards Amelioration of Alzheimer's Disease /

Record Type:	Electronic resources : Monograph/item
Title/Author:	Effects of Anti-Oxidative and Cholesterol Lowering Capacities of Selected Edible-Medicinal Mushrooms Towards Amelioration of Alzheimer's Disease // Mohammad Azizur Rahman.
Author:	Rahman, Mohammad Azizur,
Description:	1 electronic resource (313 pages)
Notes:	Source: Dissertations Abstracts International, Volume: 85-04, Section: B.
Contained By:	Dissertations Abstracts International85-04B.
Subject:	Physiology. -
Online resource:	https://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=30599456
ISBN:	9798380456579

Effects of Anti-Oxidative and Cholesterol Lowering Capacities of Selected Edible-Medicinal Mushrooms Towards Amelioration of Alzheimer's Disease /
Rahman, Mohammad Azizur,

Effects of Anti-Oxidative and Cholesterol Lowering Capacities of Selected Edible-Medicinal Mushrooms Towards Amelioration of Alzheimer's Disease /Mohammad Azizur Rahman. - 1 electronic resource (313 pages)

Source: Dissertations Abstracts International, Volume: 85-04, Section: B.

Alzheimer's disease (AD) is a neuro-degenerative disorder affecting mainly the elderly people. Though more than 40 million people are suffering from AD complications up to present date, there is hardly any treatment effective in withstanding the progression of AD. Thus, demand for natural, safe and cost-effective AD therapeutics has got momentum. Oxidative stress (OS) and increased plasma cholesterol levels have been implicated among the numerous pathomechanistic factors of AD. Despite some discrepencies, strategies aimed at lowering OS and hypercholesterolemia seems promising as AD therapeutics. Mushrooms have been highly hailed for providing numerous health benefits including anti-oxidative and hypocholesterolemic potentialities. However, combined anti-oxidative and hypocholesterolemic effect of edible-medicinal mushrooms have not been reported though these two aspects have been studied separately. Also, as an AD therapeutic agent, mushroom has not been interpreted through their anti-oxidative and hypocholesterolemic properties. Thus, the present study has been designed to elucidate the anti-oxidative, hypocholesterolemic and AD ameliorating properties of the selected edible-medicinal mushrooms: H. erinaceus, L. edodes, F. velutipes and G. lucidum. Five solvent-solvent partitioned fractions (methanol:dichloromethane, dichloromethane, hexane, ethylacetate, aqueous and hot water extract (HWE) of each of the four mushroom species were screened through in vitro anti-oxidant tests including 2,2-diphenyl-1-picrylhydrazyl (DPPH) free radical scavenging, Folin-Ciocalteu assay, lipid peroxidation (LPO) and low density lipo-protein (LDL) oxidation inhibition tests. Among all, the HWE of G. lucidum had been found possessing the best in vitro anti-oxidative capacity and highest content of polyphenols, tri-terpenoids and sterols. Thus, this mushroom extract had been chosen for the rest of the studies.In vivo anti-oxidative and hypocholesterolemic studies upon rats showed increasing effect towards plasma and liver anti-oxidant enzymes (catalase, glutathione peroxidase and superoxide dismutase) while total cholesterol (TC), triacylglycerol (TG), LDL-cholesterol were decreased and HDL-cholesterol was increasd. This mushroom extract demonstrated absence of adverse effect upon the organ function tests. As derangement of memory and learning abilities is the most notable complication associated with AD, the effect of the HWE of G. lucidum had been tested upon the AD model rats. Feeding of HWE of G. lucidum was found to improve memory and learning abilities of the AD rats. This cognitive improvement has been supported by elevated levels of memory related neurotransmitters in the respective rats. Transmission electron microscopic (TEM) studies demonstrated pronged neuronal dendrites in the G. lucidum HWE treated rats than those of the non-treated. Finally, brain comparative proteomics have identified differentially expressed proteins involved in neurotransmission, metabolism, cellular stress response and misfolding repairment. Improved functional network had been observed among the proteome of the G. lucidum HWE treated rats through STRING analysis. Ingenuity pathway analysis (IPA) identified nervous system development, cell-cell signaling and interaction, molecular transport and cell death and survival among the top-most functional networks among the experimental subjects. Thus, AD ameliorating effect of G. lucidumthrough antioxidative and hypocholesterolemic performances might be implicated in AD therapeutics.

English

ISBN: 9798380456579Subjects--Topical Terms:

518431
Physiology.

Effects of Anti-Oxidative and Cholesterol Lowering Capacities of Selected Edible-Medicinal Mushrooms Towards Amelioration of Alzheimer's Disease /
LDR:05021nmm a22004453i 4500 001 2437326
005 20251119142755.5
006 m o d
007 cr|nu||||||||
008 261011s2017 miu||||||m |||||||eng d
020 $a 9798380456579
035 $a (MiAaPQD)AAI30599456
035 $a (MiAaPQD)Malayastudentsrepoumedumy9920
035 $a AAI30599456
040 $a MiAaPQD $b eng $c MiAaPQD $e rda
100 1 $a Rahman, Mohammad Azizur, $e author. $3 3828264
245 1 0 $a Effects of Anti-Oxidative and Cholesterol Lowering Capacities of Selected Edible-Medicinal Mushrooms Towards Amelioration of Alzheimer's Disease / $c Mohammad Azizur Rahman.
264 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2017
300 $a 1 electronic resource (313 pages)
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
500 $a Source: Dissertations Abstracts International, Volume: 85-04, Section: B.
500 $a Advisors: Abdullah, Noorlidah.
502 $b Ph.D. $c University of Malaya (Malaysia) $d 2017.
520 $a Alzheimer's disease (AD) is a neuro-degenerative disorder affecting mainly the elderly people. Though more than 40 million people are suffering from AD complications up to present date, there is hardly any treatment effective in withstanding the progression of AD. Thus, demand for natural, safe and cost-effective AD therapeutics has got momentum. Oxidative stress (OS) and increased plasma cholesterol levels have been implicated among the numerous pathomechanistic factors of AD. Despite some discrepencies, strategies aimed at lowering OS and hypercholesterolemia seems promising as AD therapeutics. Mushrooms have been highly hailed for providing numerous health benefits including anti-oxidative and hypocholesterolemic potentialities. However, combined anti-oxidative and hypocholesterolemic effect of edible-medicinal mushrooms have not been reported though these two aspects have been studied separately. Also, as an AD therapeutic agent, mushroom has not been interpreted through their anti-oxidative and hypocholesterolemic properties. Thus, the present study has been designed to elucidate the anti-oxidative, hypocholesterolemic and AD ameliorating properties of the selected edible-medicinal mushrooms: H. erinaceus, L. edodes, F. velutipes and G. lucidum. Five solvent-solvent partitioned fractions (methanol:dichloromethane, dichloromethane, hexane, ethylacetate, aqueous and hot water extract (HWE) of each of the four mushroom species were screened through in vitro anti-oxidant tests including 2,2-diphenyl-1-picrylhydrazyl (DPPH) free radical scavenging, Folin-Ciocalteu assay, lipid peroxidation (LPO) and low density lipo-protein (LDL) oxidation inhibition tests. Among all, the HWE of G. lucidum had been found possessing the best in vitro anti-oxidative capacity and highest content of polyphenols, tri-terpenoids and sterols. Thus, this mushroom extract had been chosen for the rest of the studies.In vivo anti-oxidative and hypocholesterolemic studies upon rats showed increasing effect towards plasma and liver anti-oxidant enzymes (catalase, glutathione peroxidase and superoxide dismutase) while total cholesterol (TC), triacylglycerol (TG), LDL-cholesterol were decreased and HDL-cholesterol was increasd. This mushroom extract demonstrated absence of adverse effect upon the organ function tests. As derangement of memory and learning abilities is the most notable complication associated with AD, the effect of the HWE of G. lucidum had been tested upon the AD model rats. Feeding of HWE of G. lucidum was found to improve memory and learning abilities of the AD rats. This cognitive improvement has been supported by elevated levels of memory related neurotransmitters in the respective rats. Transmission electron microscopic (TEM) studies demonstrated pronged neuronal dendrites in the G. lucidum HWE treated rats than those of the non-treated. Finally, brain comparative proteomics have identified differentially expressed proteins involved in neurotransmission, metabolism, cellular stress response and misfolding repairment. Improved functional network had been observed among the proteome of the G. lucidum HWE treated rats through STRING analysis. Ingenuity pathway analysis (IPA) identified nervous system development, cell-cell signaling and interaction, molecular transport and cell death and survival among the top-most functional networks among the experimental subjects. Thus, AD ameliorating effect of G. lucidumthrough antioxidative and hypocholesterolemic performances might be implicated in AD therapeutics.
546 $a English
590 $a School code: 1293
650 4 $a Physiology. $3 518431
650 4 $a Plasma. $3 877619
650 4 $a Mushrooms. $3 555435
650 4 $a Acids. $3 922327
650 4 $a Memory. $3 522110
650 4 $a Free radicals. $3 3682274
650 4 $a Disease. $3 705846
650 4 $a Brain research. $3 3561789
650 4 $a Immunology. $3 611031
650 4 $a Cholesterol. $3 3382101
650 4 $a Drugs. $3 617161
650 4 $a Lipids. $3 558980
650 4 $a Oxidative stress. $3 899116
650 4 $a Mass spectrometry. $3 551172
650 4 $a Statins. $3 3828265
650 4 $a Oxidation. $3 714629
650 4 $a Solvents. $3 620946
650 4 $a Functional foods & nutraceuticals. $3 3691969
650 4 $a Proteomics. $3 600542
650 4 $a Analytical chemistry. $3 3168300
650 4 $a Bioinformatics. $3 553671
650 4 $a Chemistry. $3 516420
650 4 $a Food science. $3 3173303
650 4 $a Neurosciences. $3 588700
650 4 $a Pharmaceutical sciences. $3 3173021
690 $a 0982
690 $a 0719
690 $a 0486
690 $a 0715
690 $a 0485
690 $a 0359
690 $a 0317
690 $a 0572
710 2 $a University of Malaya (Malaysia). $e degree granting institution. $3 3765814
720 1 $a Abdullah, Noorlidah $e degree supervisor.
773 0 $t Dissertations Abstracts International $g 85-04B.
790 $a 1293
791 $a Ph.D.
792 $a 2017
856 4 0 $u https://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=30599456